Immunoprecise Share Are Trading Higher On Encouraging Preclinical Data Of COVID-19 Antibody Cocktail

Immunoprecise Antibodies Ltd IPA has announced additional results from its in vivo hamster challenge efficacy study of TATX-03a PolyTope Therapy, a four monoclonal antibody cocktail for COVID-19.
Data showed reduced bronchitis and tracheitis inflammation severity in animal models compared to study control animals.
In addition, only mild inflammation of the trachea was observed in animals treated with TATX-03a post-challenge.
The Company concurrently announced optimization results of TATX-03 cocktail components designed to improve clinical suitability.
The optimization focused on removing sites in the antigen-binding fragment that might not be fully processed during clinical development, potentially reducing clinical manufacturing yields.
The Company continues to plan for IND submission of TATX-03 to pursue human clinical studies evaluating the potential of the cocktail to protect or treat COVID-19 patients.
Immunoprecise is conducting a webinar today at 11:00 a.m. ET.
Price Action: IPA shares are up 3.54% at $7.47 during the market session on the last check Thursday.